Germline HA Mechanotransduction Locks HAS2 Expression via a YAP/TAZ‑Dependent Epigenetic Circuit

Hypothesis

Germline cells sustain high‑molecular‑weight hyaluronan (HMW‑HA) through a self‑reinforcing mechanotransduction loop in which HMW‑HA engages the LYVE‑1/RHAMM complex, activates nuclear YAP/TAZ, and maintains an open, acetylated chromatin state at the HAS2 promoter. This epigenetic lock prevents the age‑related silencing seen in somatic lineages, effectively giving the germline a "cheating" edge that is not based on superior repair but on continuous HA‑driven transcriptional activation.

Mechanistic Model

1. HA‑Receptor Engagement – HMW‑HA binds LYVE‑1 (or RHAMM) on the plasma membrane, triggering Src‑family kinase signaling that phosphorylates YAP/TAZ, preventing Hippo‑mediated cytoplasmic retention【https://doi.org/10.1016/j.cell.2018.05.018】.
2. Nuclear YAP/TAZ Action – Nuclear YAP/TAZ recruit p300/CBP histone acetyltransferases to the HAS2 promoter, increasing H3K27ac and preserving transcriptional competence【https://www.nature.com/articles/nrg3000】.
3. Feedback Amplification – Elevated HAS2 synthesis yields more HMW‑HA, further stimulating the receptor‑YAP/TAZ axis. In somatic cells, declining HMW‑HA reduces LYVE‑1 signaling, YAP/TAZ exit the nucleus, HDACs deacetylate the HAS2 locus, and HAS2 transcription drops, permitting LMW‑HA accumulation and TLR/CD44‑driven NF‑κB inflammaging【https://pmc.ncbi.nlm.nih.gov/articles/PMC6746454/】【https://pmc.ncbi.nlm.nih.gov/articles/PMC5760314/】【https://pubmed.ncbi.nlm.nih.gov/29196459/】.
4. Epigenetic Memory – Germline‑specific histone variants (e.g., H3.3) and low DNA methylation at the HAS2 CpG island reinforce resistance to silencing, a state that somatic chromatin gradually loses with age.

Testable Predictions

• Prediction 1: Pharmacological activation of YAP/TAZ (e.g., using verteporfin withdrawal or overexpression of a constitutively nuclear YAP‑S127A) in aged dermal fibroblasts will increase HAS2 mRNA, raise HMW‑HA/HAS2 protein, and reduce TLR4‑NF‑κB signaling after LMW‑HA challenge.
• Prediction 2: CRISPR‑mediated deletion of LYVE‑1 in mouse oocytes or spermatogonia will cause age‑dependent decline in HMW‑HA, increased LMW‑HA fragments, and heightened ovarian/testicular inflammatory markers, demonstrating germline reliance on this receptor.
• Prediction 3: Chromatin immunoprecipitation (ChIP) for H3K27ac and YAP at the HAS2 promoter will show enrichment in young germline cells and loss in aged somatic fibroblasts; rescuing YAP nuclear localization will restore the acetylation pattern.
• Prediction 4: Treating somatic cells with exogenous HMW‑HA (≥1 MDa) will mimic the germline signal, activating LYVE‑1/YAP/TAZ and delaying senescence‑associated secretory phenotype (SASP) in a dose‑dependent manner, whereas LMW‑HA will not.

Falsifiability

If YAP/TAZ activation fails to elevate HAS2 or HMW‑HA in aged fibroblasts, or if LYVE‑1 loss in germ cells does not alter HA size distribution or inflammatory readouts, the proposed mechanotransduction‑epigenetic loop would be refuted. Likewise, if exogenous HMW‑HA does not suppress NF‑κB activity in somatic cells, the HA‑mediated feedback would be insufficient to explain germline HA homeostasis.

Broader Implication

Viewing the germline's "immortality" as a tunable HA‑YAP/TAZ epigenetic circuit reframes the cheating strategy: it is not an immutable barrier but a signaling state that can be experimentally transferred to somatic compartments, offering a concrete route to engineer somatic cells with a germline‑grade editing budget for HA homeostasis.